Tatsunori Iwamura, 61, professor of pharmaceutical sciences at Japan's Matsuyama University, was busted for teaching his students how to make MDMA (aka Molly/Ecstasy) and 5F-QUPIC, a cannabinoid agonist. At some point, Iwamura had a license to manufacture illegal drugs for academic purposes but it had expired. From The Guardian:
Read the rest
Local drug enforcement authorities believe 11 students produced the drug (MDMA) under Iwamura’s instruction. Four students, along with an assistant professor, have also been referred to prosecutors, Kyodo said.
The university said it would discipline Iwamura and the assistant professor once the investigation had ended.
“We sincerely apologise for causing serious concern to students and their parents,” said Tatsuya Mizogami, the university’s president, according to Kyodo.
The active ingredient in Ecstasy, MDMA, is safe and can help to treat post-traumatic stress disorder, a new clinical psychotherapy trial shows.
Read the rest
The Multidisciplinary Association for Psychedelic Studies announced that the FDA has granted MDMA (aka Ecstasy/Molly) a "Breakthrough Therapy" designation as part of a treatment for posttraumatic stress disorder (PTSD). From the journal Science:
Read the rest
One of the main targets in the war on drugs could well become a drug to treat the scars of war. The U.S. Food and Drug Administration (FDA) has designated 3,4-methylenedioxymethamphetamine (MDMA), better known as the illegal drug ecstasy, a "breakthrough therapy" for posttraumatic stress disorder (PTSD), a status that may lead to faster approval.
The agency has also approved the design for two phase III studies of MDMA for PTSD that would be funded by the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit in Santa Cruz, California. MAPS announced the "breakthrough therapy" designation, made by FDA on 16 August, on its website today; if the group can find the money for the trials, which together could cost an estimated $25 million, they may start next spring and finish by 2021.
That an illegal dancefloor drug could become a promising pharmaceutical is another indication that the efforts of a dedicated group of researchers interested in the medicinal properties of mind-altering drugs is paying dividends. Stringent drug laws have stymied research on these compounds for decades. "This is not a big scientific step," says David Nutt, a neuropsychopharmacologist at Imperial College London. "It’s been obvious for 40 years that these drugs are medicines. But it’s a huge step in acceptance."
“Are you gonna keep dancing forever?”
“Yeah. Forever. Or until I remember where my car is.” Read the rest
Katy Perry invited a KatyCat named Rayane to join her onstage in Rio, and the young woman couldn't help herself from squeezing, neck-kissing, and licking Katy, who handled the ecstasy-fueled gropiung with professional aplomb. Read the rest
Under the supervision of a medical team, New Scientist's Graham Lawton took a dose of MDMA and then lay in an fMRI machine. You know. For science.
Lawton was a participant in a double blind, controlled, clinical study — meaning that he didn't actually know whether he was going to be taking ecstasy or Vitamin C when he went in ... and neither did the scientists who gave him the pill. That's because the researchers want to know whether and what differences show up between the functioning of brain under the influence of MDMA and one that's sober. Not knowing which type of brain they're looking at helps them avoid their own biases, or tendencies to "spot" a difference that doesn't actually exist simply because of what they expect a high brain (or a sober one) to be doing. Only after they've made their observations do the scientists find out which brains were which.
The goal is to document was ecstasy does to the brain. Astoundingly, writes Lawton, nobody has ever done that before. And it matters, because some people think that drugs like ecstasy could be useful in helping people deal with psychological stress disorders. Not that the drugs would cure the disorder, per se, but that ecstasy could help people talk about their bad experiences more easily. Right now, there's not a lot of evidence supporting that idea, beyond some anecdotes. Studies like this help scientists figure out whether the anecdotes are pointing at a useful treatment tool, or just relating some personal experiences. Read the rest